Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Riess

Showing results (1231-1240 of 1,489) with videos related to

Pageof 149
Sort By:
Frontiers in Oncology|March 18, 2021
Case Report: Combined CDK4/6 and MEK Inhibition in Refractory CDKN2A and NRAS Mutant MelanomaAndrea Forschner, Tobias Sinnberg, Gabi Mroz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2018
Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic ClearanceDavid C Turner, Anna G Kondic, Keaven M Anderson, et al.
Journal of Thoracic Imaging|December 9, 2017
Computed Tomography Features associated With the Eighth Edition TNM Stage Classification for Thymic Epithelial TumorsSukhmani K Padda, Donato Terrone, Lu Tian, et al.
Frontiers in Molecular Neuroscience|October 27, 2018
Mitochondrial Morphology, Function and Homeostasis Are Impaired by Expression of an N-terminal Calpain Cleavage Fragment of Ataxin-3Tina Harmuth, Caroline Prell-Schicker, Jonasz J Weber, et al.
Human Molecular Genetics|March 13, 2014
Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-Synuclein processing, aggregation and synaptic impairment in [A30P]αSyn transgenic miceMeike Diepenbroek, Nicolas Casadei, Hakan Esmer, et al.
The Oncologist|August 9, 2019
MET Genomic Alterations in Head and Neck Squamous Cell Carcinoma (HNSCC): Rapid Response to Crizotinib in a Patient with HNSCC with a Novel <i>MET</i> R1004G MutationLisa Pei Chu, Debra Franck, Christine A Parachoniak, et al.
Cell Death & Disease|April 19, 2014
Mitochondrial proteolytic stress induced by loss of mortalin function is rescued by Parkin and PINK1L F Burbulla, J C Fitzgerald, K Stegen, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|December 29, 2004
The role of alpha-synuclein gene multiplications in early-onset Parkinson's disease and dementia with Lewy bodiesA Hofer, D Berg, F Asmus, et al.
JCO Precision Oncology|June 4, 2025
ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line OsimertinibJonathan W Riess, Adrianus J de Langen, Santiago Ponce, et al.
Clinical Lung Cancer|November 24, 2020
Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study DesignJonathan W Riess, Paul Frankel, David Shackelford, et al.
Pageof 149

Showing results (1231-1240 of 1,489) with videos related to

Sort By:
Pageof 149
Frontiers in Oncology|March 18, 2021
Case Report: Combined CDK4/6 and MEK Inhibition in Refractory CDKN2A and NRAS Mutant MelanomaAndrea Forschner, Tobias Sinnberg, Gabi Mroz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2018
Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic ClearanceDavid C Turner, Anna G Kondic, Keaven M Anderson, et al.
Journal of Thoracic Imaging|December 9, 2017
Computed Tomography Features associated With the Eighth Edition TNM Stage Classification for Thymic Epithelial TumorsSukhmani K Padda, Donato Terrone, Lu Tian, et al.
Frontiers in Molecular Neuroscience|October 27, 2018
Mitochondrial Morphology, Function and Homeostasis Are Impaired by Expression of an N-terminal Calpain Cleavage Fragment of Ataxin-3Tina Harmuth, Caroline Prell-Schicker, Jonasz J Weber, et al.
Human Molecular Genetics|March 13, 2014
Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-Synuclein processing, aggregation and synaptic impairment in [A30P]αSyn transgenic miceMeike Diepenbroek, Nicolas Casadei, Hakan Esmer, et al.
The Oncologist|August 9, 2019
MET Genomic Alterations in Head and Neck Squamous Cell Carcinoma (HNSCC): Rapid Response to Crizotinib in a Patient with HNSCC with a Novel <i>MET</i> R1004G MutationLisa Pei Chu, Debra Franck, Christine A Parachoniak, et al.
Cell Death & Disease|April 19, 2014
Mitochondrial proteolytic stress induced by loss of mortalin function is rescued by Parkin and PINK1L F Burbulla, J C Fitzgerald, K Stegen, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|December 29, 2004
The role of alpha-synuclein gene multiplications in early-onset Parkinson's disease and dementia with Lewy bodiesA Hofer, D Berg, F Asmus, et al.
JCO Precision Oncology|June 4, 2025
ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line OsimertinibJonathan W Riess, Adrianus J de Langen, Santiago Ponce, et al.
Clinical Lung Cancer|November 24, 2020
Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study DesignJonathan W Riess, Paul Frankel, David Shackelford, et al.
Pageof 149